Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, Founder and...
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
September 01, 2022 06:30 ET
|
Vaxart, Inc.
— Study met primary safety and secondary immunogenicity endpoints — — Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects — — Elicited cross-reactive...
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
August 31, 2022 16:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced it will release top-line data from the first part of its planned two-part COVID-19 Phase II...
Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer
August 31, 2022 08:30 ET
|
Vaxart, Inc.
Dr. Stapleton has more than 20 years of industry experience leading technical, quality and manufacturing operations at commercial and clinical stage biopharmaceutical companies SOUTH SAN...
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
August 25, 2022 16:05 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Elaine J. Heron, Ph.D. was appointed to the Company’s Board of Directors,...
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
Vaxart, Inc.
Top-line data from COVID-19 Phase II study expected in the third quarter of 2022 Vaxart initiates work on vaccine candidates that directly target new omicron variants of concern Positive data from...
Vaxart Appoints W. Mark Watson to its Board of Directors
August 08, 2022 08:00 ET
|
Vaxart, Inc.
Non-executive director to bring extensive life science industry and finance experience SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced...
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
August 05, 2022 08:00 ET
|
Vaxart, Inc.
All six proposals approved in the 2022 Proxy Statement Vote strengthens the Company as it progresses its oral vaccine programs SOUTH SAN FRANCISCO, Calif., Aug. 05, 2022 (GLOBE NEWSWIRE) --...
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
July 28, 2022 16:05 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended...
Vaxart biedt nieuwe update over stemmen bij volmacht en dringt er bij alle op 11 april 2022 geregistreerde aandeelhouders op aan om vóór 3 augustus 2022 om 23:59 uur ET te stemmen
July 27, 2022 15:28 ET
|
Vaxart, Inc.
Het hoofdvoorstel #2 heeft nog 0,9% van de uitstaande aandelenstemmen nodig om aangenomen te worden Toonaangevende onafhankelijke stemadviesbureaus, ISS en Glass Lewis, ondersteunen het voorstel #2 ...